Zentalis Pharmaceuticals Inc (ZNTL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Zentalis Pharmaceuticals Inc   (NASDAQ: ZNTL)


Zentalis Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Zentalis Pharmaceuticals Inc's ROI in the second quarter of 2026?
Zentalis Pharmaceuticals Inc recorded a cumulative net loss of $-140 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -59.51%.

Within the Healthcare sector 524 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3600 to 3697.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM -33.97 % -30.01 % -30.06 % -27.18 % -26.66 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 178 218 252 290 313
Return On Investment (TTM) -59.51 % -46.27 % -46.08 % -45.42 % -45.83 %
ZNTL's Overall Ranking # 3697 # 3600 # 3273 # 3513 # 3407
Seq. Investment Change TTM -12.58 % -9.81 % -9.52 % -7.44 % -7.33 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -140 -124 -137 -149 -163

ZNTL Company Profile >> Back to ZNTL Roi Comparisons >> See Annual ZNTL Return On Investment



Return On Investment ZNTL's Ranking
Within: No.
Industry # 229
Sector # 525
Overall # 3697

Return On Investment Statistics
High Average Low
-13.22 %
-45.11 %
-74.73 %
(Dec 31 2020)   (Jun 30 2023)



  News about Zentalis Pharmaceuticals Inc Return on Investment ROI

Zentalis Pharmaceuticals: Navigating Leadership Changes Amid Financial Struggles and Strategic Talent Acquisition

November 13, 2024

In a whirlwind of activity, Zentalis Pharmaceuticals finds itself at a pivotal juncture, marked by significant executive leadership changes, alarming financial metrics, and an aggressive strategy to attract top talent. These developments are essential to understanding the company s trajectory as it seeks to secure a foothold in the highly competitive biopharmaceutical landscape.Leadership TransformationThe recent appointment of Julie Eastland as the new Chief Executive Officer, President, and Director signals a strategic shift in Zentalis Pharmaceuticals approach to corporate governance and operational execution. Such changes at the executive level often reflect a company’s urgent need for fresh perspectives and strategies — especially in the clinical-stage biopharmaceutical sector, where innovation is the lifeblood of success. Eastland s leadership will be scrutinized as Zentalis gears up for critical registrational clinical studies for its lead candidate, Azenosertib, which targets pivotal biological pathways in cancer treatment.

Zentalis Pharmaceuticals Appoints Accomplished Oncologist, Dr. Diana Hausman, as Chief Medical Officer in a Bid to Overcome Market Downturn.

January 25, 2024

Zentalis Pharmaceuticals Bolsters Leadership Team and Aims to Reverse Market Downturn
In an effort to navigate through a challenging market period, Zentalis Pharmaceuticals Inc. has made significant strides in strengthening its management team with key appointments. The company has recently announced the addition of Dr. Diana Hausman, an accomplished oncologist and drug developer, to its ranks as the new Chief Medical Officer. This strategic move comes at a time when Zentalis Pharmaceuticals shares are currently trading on the NASDAQ at a staggering -34% below its 52-week average.
Dr. Hausman brings a wealth of experience and expertise to her role as Chief Medical Officer at Zentalis Pharmaceuticals. With prior accomplishments in oncology and drug development, her appointment signifies the company s commitment to developing and advancing innovative treatments in the field of oncology. As a reputable and esteemed professional, Dr. Hausman s arrival is expected to bolster the research and development efforts at Zentalis Pharmaceuticals significantly.





Financial Statements
Zentalis Pharmaceuticals Inc's II. Quarter Investments $ 178 Millions ZNTL's Balance sheet
Zentalis Pharmaceuticals Inc's II. Quarter Income $ -42 Millions Quarterly ZNTL's Income Statement
ZNTL's Income by Division See ZNTL's Income by Division


ZNTL Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 252 378 482 916 748
Y / Y Investment Growth -33.16 % -21.73 % -47.36 % 22.51 % -41.89 %
Net Income in Millions -137 -166 -292 -237 -166
Y / Y Net Income Growth - - - - -
Annual Return On Investment -54.3 % -43.93 % -60.59 % -25.87 % -22.2 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ZNTL's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ZNTL's Competitors
Subscribers only: Roi for Zentalis Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ZNTL's Customers

Other Ratios
ZNTL's Roa ZNTL's Inventory Turnover Ratio ZNTL's Growth Rates ZNTL's Dividend Statistics
ZNTL's Profitability Ratios ZNTL's Asset Turnover Ratio ZNTL's Dividend Growth
ZNTL's Roe ZNTL's Valuation Ratios ZNTL's Financial Strength Ratios ZNTL's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-05T15:41:29+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.